AMRX
Amneal Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$21.35
+0.99%Oct 8, 2026, 12:00 UTC
Amneal Pharmaceuticals announced that it will report its third-quarter 2026 financial results before market open on November 3, 2026, and host an audio webcast at 8:30 a.m. ET.
Source:Sep 18, 2026, 20:01 UTC
The FDA approved Amneal Pharmaceuticals' Lanreotide Injection, a long-acting oncology treatment, and Amneal immediately launched the product commercially.
Sep 17, 2026, 13:20 UTC
Amneal Pharmaceuticals (AMRX) shares surged 8.6% in the prior session on above-average trading volume.
Source:Aug 10, 2026, 12:00 UTC
Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences, creating an integrated global biosimilar platform covering R&D, manufacturing, and commercialization.
Source:Aug 10, 2026, 00:00 UTC
Amneal Pharmaceuticals entered into Amendment No. 4 to its term loan credit agreement, creating a $350 million new incremental term loan to partially finance its acquisition of Kashiv BioSciences.
Jul 30, 2026, 10:00 UTC
Amneal Pharmaceuticals reported its financial results for the second quarter of 2026, with net revenue of $796 million, GAAP net income of $58 million, and diluted earnings per share of $0.18.
Jul 17, 2026, 12:00 UTC
Amneal Pharmaceuticals received U.S. FDA approval for additional strengths and vial presentations of iohexol injection.
Source:Jun 29, 2026, 07:00 UTC
The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of Hopledo (IPX203) for adults with Parkinson's disease and moderate to severe motor fluctuations.
Source:Jun 5, 2026, 16:30 UTC
Amneal Pharmaceuticals received FDA approval for its ready-to-use romidepsin injection solution, with 180-day exclusivity.
Source:Jun 4, 2026, 12:00 UTC
Amneal Pharmaceuticals received U.S. FDA approval for its romidepsin injection solution, a ready-to-use formulation for injection.